News Sentiment

NRIX sentiment intelligence

Nurix Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 56 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 23.06 Week of 10 Jul 2026
Weighted tone 56/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

72/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 5

high-authority source matches

Trend context Trend active

-3.8% over one week, +36.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Positive

Nurix Therapeutics, Inc. Stock 12‑Month Price Target Raised to $32.87, Implies 42% Upside

Market Reaction

Balanced read

62/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 72/100 classification
One-week reaction -3.8% Price reacting lower
Trend fit Trend active 36.0% over four weeks
Fair value 56.9% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 31
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 10
MarketBeat 9
Stock Titan 9
TradingView 5
simplywall.st 4
Moomoo 3
Seeking Alpha 3
Investing.com 2

Event Lens

What the news is about

Classified themes
Earnings 24
Market update 20
Analyst action 13
Deals and strategy 5

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 62
marketscreener.com Direct company coverage

Earnings Flash (NRIX) Nurix Therapeutics, Inc. Reports Q2 Revenue $9.0M, vs. FactSet Est of $15.3M

Nurix Therapeutics, Inc. (NRIX) reported its Q2 revenue at $9.0 million, significantly missing the FactSet estimate of $15.3 million. This earnings flash highlights that the company's Q2 loss widened and revenue fell, indicating a weaker financial performance than anticipated by

Tone
Neutral 50/100
Event
Earnings
Published
09 Jul 2026 16:04
Source
marketscreener.com
Investing.com Nigeria Direct company coverage

Nurix Therapeutics stock hits 52-week high at $24.93 By Investing.com

Nurix Therapeutics Inc. stock has reached a 52-week high of $24.93, reflecting a 94.63% increase over the past year. This surge follows positive clinical trial results for its BTK degrader, bexobrutideg, and a significant collaboration agreement with Roche, despite InvestingPro i

Tone
Positive 72/100
Event
Earnings
Published
09 Jul 2026 15:06
Source
Investing.com Nigeria